Background: The prevalence of diabetes mellitus (DM) is rapidly increasing worldwide. Metrnl and asprosin are the new adipomyokins that can increase glucose tolerance and affect insulin resistance. Based on this information, we aimed to identify the possible relationship between T2DM and asprosin, Metrnl levels and insulin resistance.
Methods: Our study consisted of a group of 60 patients (female: 30/male: 30) who were newly diagnosed with T2DM and did not take any medications and a control group of 60 healthy (female: 31 - male: 29) individuals.
Results: We found that serum Metrnl levels were significantly lower in the diabetic group than in the control group (p < 0.01). In contrast, serum asprosin levels were significantly higher in the diabetic group compared to the control group (p < 0.01). We found a positive correlation between asprosin levels and HOMA-IR, insulin, BMI, and triglyceride levels in the patient group. On the contrary, we found a negative correlation between Metrnl levels and HOMA-IR, insulin, triglyceride, glucose levels.
Conclusions: In the literature review, we could not find a comparison study on the relationship between T2DM, Metrnl, asprosin levels, and HOMA-IR in humans. As far as we know, this study will be the first report in which both adipokine/adipomyokine are compared and associated with HOMA-IR. Asprosin levels in patients with T2DM are higher than healthy people, and Metrnl levels are lower. These two molecules (Metrnl and asprosin) have the ability to be an early warning signal of insulin resistance for T2DM.